You are here: Home » PTI Stories » National » News
Business Standard

Lupin partners Eli Lilly to market diabetes drug 'Eglucent'

Press Trust of India  |  New Delhi 

Pharma major today announced a new partnership with Eli Lilly to market and sell the latter's diabetes treatment drug 'Eglucent' in the country.

"According to the agreement, will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import," said in a filing.



It further said: "Eli Lilly and Company (India) Pvt Ltd (Lilly) will continue to sell Lispro under the brand name Humalog through its existing channels".

had earlier collaborated with Lilly in July, 2011 to promote and distribute Lilly's Huminsulin range of products in and Nepal.

Eli Lilly and Company (India) Pvt Ltd is a subsidiary of the US pharmaceutical major Eli Lilly and Company.

Eglucent, a new brand of Lilly's rapid-acting insulin analog Lispro, is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes.

"The intent of this launch, which is the first for Lilly in the entire Emerging Markets region, is to increase the reach of analog insulin Lispro to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India," Lilly Managing Director Edgard Olaizola said.

Group President, Region Formulations Shakti Chakraborty said "our entry into the rapid-acting Insulin analog segment will not only bolster our existing Diabetes portfolio but will also go a long way in strengthening our position in the Indian Pharmaceutical market."

Eglucent will be available in the Indian market in both, the cartridge and disposable pen form.

said it is the fifth largest company in the "anti-Diabetes segment with a market share of 6.34 per cent growing at 18 per cent (IMS MAT September 2016)" and its anti-diabetic portfolio contributes 11 per cent to its formulations sales.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Lupin partners Eli Lilly to market diabetes drug 'Eglucent'

Pharma major Lupin today announced a new partnership with Eli Lilly India to market and sell the latter's diabetes treatment drug 'Eglucent' in the country. "According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import," Lupin said in a BSE filing. It further said: "Eli Lilly and Company (India) Pvt Ltd (Lilly) will continue to sell Lispro under the brand name Humalog through its existing channels". Lupin had earlier collaborated with Lilly in July, 2011 to promote and distribute Lilly's Huminsulin range of products in India and Nepal. Eli Lilly and Company (India) Pvt Ltd is a subsidiary of the US pharmaceutical major Eli Lilly and Company. Eglucent, a new brand of Lilly's rapid-acting insulin analog Lispro, is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 ... Pharma major today announced a new partnership with Eli Lilly to market and sell the latter's diabetes treatment drug 'Eglucent' in the country.

"According to the agreement, will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import," said in a filing.

It further said: "Eli Lilly and Company (India) Pvt Ltd (Lilly) will continue to sell Lispro under the brand name Humalog through its existing channels".

had earlier collaborated with Lilly in July, 2011 to promote and distribute Lilly's Huminsulin range of products in and Nepal.

Eli Lilly and Company (India) Pvt Ltd is a subsidiary of the US pharmaceutical major Eli Lilly and Company.

Eglucent, a new brand of Lilly's rapid-acting insulin analog Lispro, is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes.

"The intent of this launch, which is the first for Lilly in the entire Emerging Markets region, is to increase the reach of analog insulin Lispro to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India," Lilly Managing Director Edgard Olaizola said.

Group President, Region Formulations Shakti Chakraborty said "our entry into the rapid-acting Insulin analog segment will not only bolster our existing Diabetes portfolio but will also go a long way in strengthening our position in the Indian Pharmaceutical market."

Eglucent will be available in the Indian market in both, the cartridge and disposable pen form.

said it is the fifth largest company in the "anti-Diabetes segment with a market share of 6.34 per cent growing at 18 per cent (IMS MAT September 2016)" and its anti-diabetic portfolio contributes 11 per cent to its formulations sales.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Lupin partners Eli Lilly to market diabetes drug 'Eglucent'

Pharma major today announced a new partnership with Eli Lilly to market and sell the latter's diabetes treatment drug 'Eglucent' in the country.

"According to the agreement, will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import," said in a filing.

It further said: "Eli Lilly and Company (India) Pvt Ltd (Lilly) will continue to sell Lispro under the brand name Humalog through its existing channels".

had earlier collaborated with Lilly in July, 2011 to promote and distribute Lilly's Huminsulin range of products in and Nepal.

Eli Lilly and Company (India) Pvt Ltd is a subsidiary of the US pharmaceutical major Eli Lilly and Company.

Eglucent, a new brand of Lilly's rapid-acting insulin analog Lispro, is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes.

"The intent of this launch, which is the first for Lilly in the entire Emerging Markets region, is to increase the reach of analog insulin Lispro to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India," Lilly Managing Director Edgard Olaizola said.

Group President, Region Formulations Shakti Chakraborty said "our entry into the rapid-acting Insulin analog segment will not only bolster our existing Diabetes portfolio but will also go a long way in strengthening our position in the Indian Pharmaceutical market."

Eglucent will be available in the Indian market in both, the cartridge and disposable pen form.

said it is the fifth largest company in the "anti-Diabetes segment with a market share of 6.34 per cent growing at 18 per cent (IMS MAT September 2016)" and its anti-diabetic portfolio contributes 11 per cent to its formulations sales.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard